Please assess the completion status of the following clinical trial:

Trial Title: Phase III Insulin Add-On Asia Regional Program - ST

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must have type 2 diabetes with inadequate glycemic control, defined as HbA1c ≥ 7.5% and ≤ 11.0% obtained at screening visit~* Subjects must be taking a stable mean dose of ≥ 20 IU injectable insulin daily for at least 8 weeks prior to enrollment~Inclusion criteria for randomization:~HbA1c ≥ 7.5 and ≤ 10.5% at Day -14~Exclusion Criteria:~* Treatment with more than two oral antidiabetic (OAD) agents within 6 weeks of Enrollment~* History of diabetic ketoacidosis of hyperosmolar nonketotic coma~* Clinically diagnosed Type 1 diabetes mellitus~* Congestive heart failure defined as New York Heart Association (NYHA) stage III and IV~* Severe uncontrolled hypertension defined as systolic blood pressure (SBP) ≥ 180 mmHg and/or diastolic blood pressure (DBP) ≥ 110 mmHg~* History of unstable or rapidly progressing renal disease~* History of severe hepatobiliary disease~* Mallingancy within 5 years of the screening/enrollment visit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1: Dapagliflozin (Type: EXPERIMENTAL): Dapagliflozin 10 mg oral Tablet once daily for 24 weeks + Background Insulin
- Group 2: Dapagliflozin Placebo (Type: PLACEBO_COMPARATOR): Dapagliflozin Placebo 0 mg oral Tablet once daily for 24 weeks + Background Insulin

Based on this trial design, predict the completion outcome and termination type (if applicable).